18 and older, any sex, with Cord Compression. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Ambulatory StatusPrimary· 1 month
-Ambulatory status is categorized as paraplegic, not ambulatory, ambulatory with aid (for example, with assistive device like walker or crutches), and ambulatory without aid.
Paraplegic
Group
Value
95% CI
Nab-Paclitaxel and Radiation Therapy
0
Not ambulatory
Group
Value
95% CI
Nab-Paclitaxel and Radiation Therapy
1
Ambulatory with aid
Group
Value
95% CI
Nab-Paclitaxel and Radiation Therapy
0
Ambulatory without aid
Group
Value
95% CI
Nab-Paclitaxel and Radiation Therapy
0
Strength of Lower ExtremitiesSecondary· 1 month
-Strength assessment is categorized as follows: 0/5=no contraction (worst); 1/5=muscle flicker, but no movement; 2/5=movement possible, but not against gravity (test the joint in its horizontal plane); 3/5=movement possible against gravity, but not against resistance by the examiner; 4/5=movement possible against some resistance by the examiner; 5/5=normal strength (best)
0=no contraction
Group
Value
95% CI
Nab-Paclitaxel and Radiation Therapy
0
1=muscle flicker, but no movement
Group
Value
95% CI
Nab-Paclitaxel and Radiation Therapy
0
2=movement possible, but not against gravity (test the joint in its horizontal plane)
Group
Value
95% CI
Nab-Paclitaxel and Radiation Therapy
0
3=movement possible against gravity, but not against resistance by the examiner
Group
Value
95% CI
Nab-Paclitaxel and Radiation Therapy
1
4=movement possible against some resistance by the examiner
Group
Value
95% CI
Nab-Paclitaxel and Radiation Therapy
0
5=normal strength
Group
Value
95% CI
Nab-Paclitaxel and Radiation Therapy
0
Pain in the Irradiated Area" Measured on a ScaleSecondary· 1 month
-Pain is measured on a scale between 0-10. 0=no pain (best) and 10=the greatest pain (worst)
0
Group
Value
95% CI
Nab-Paclitaxel and Radiation Therapy
0
1
Group
Value
95% CI
Nab-Paclitaxel and Radiation Therapy
0
2
Group
Value
95% CI
Nab-Paclitaxel and Radiation Therapy
0
3
Group
Value
95% CI
Nab-Paclitaxel and Radiation Therapy
0
4
Group
Value
95% CI
Nab-Paclitaxel and Radiation Therapy
0
5
Group
Value
95% CI
Nab-Paclitaxel and Radiation Therapy
1
6
Group
Value
95% CI
Nab-Paclitaxel and Radiation Therapy
0
7
Group
Value
95% CI
Nab-Paclitaxel and Radiation Therapy
0
Adverse events — posted to ClinicalTrials.gov
Time frame: From start of treatment through 28 days after completion of treatment (estimated to be 6 weeks) . Late toxicities for radiation therapy will be collected for 1 year after the end of radiation therapy (estimated to be 1 year and 2 weeks).
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this research study is to look at a combination treatment of radiation therapy and a drug called Abraxane to treat epidural spinal cord compression.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT06990061 — Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm,
· NA
· not yet recruiting
NCT06831526 — Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma
· EARLY_PHASE1
· recruiting
NCT05608369 — Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
· Phase 2
· withdrawn
NCT06702033 — The Minimalist Trial-2
· Phase 2
· recruiting
NCT06583070 — SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer
· recruiting
Other Washington University School of Medicine trials
Trials by the same sponsor.
NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
· Phase 2
· not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer
· Phase 2
· not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
· Phase 1
· not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients
· not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial)
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 4 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03655080.